|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2021 L Street NW, Suite 900 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 59171-12
|
||||||||
|
6. House ID# 352060000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Suzanne M. Leous |
Date | 7/20/2020 3:47:23 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Public health program funding
Federal research funding
FY 2021 NIH funding
FY 2021 funding for CDC Sickle Cell Disease Data Collection Program
FY 2021 funding for HRSA SCD Demonstration Program
Emergency funding for relief for coronavirus-related research disruptions/restarts
H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Suzanne |
Leous |
MPA |
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Sickle cell disease/trait issues
Hematology/oncology treatment issues
General hematology public health and research issues
Fetal tissue research
Protecting Cures Act of 2020 (H.R. 6417)
Open access policy for peer reviewed research journals
Issues impacting blood safety/shortages
Issues related to convalescent plasma
Issues impacting delivery of bone marrow, peripheral blood, and cord blood
Issues related to implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748/P.L. 116-136)
H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Suzanne |
Leous |
MPA |
|
|
Stephanie |
Kaplan |
|
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Coverage of blood transfusions under Medicare Hospice Benefit
Reimbursement for CAR-T/cellular and gene therapies
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10)
Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)
CMS national coverage determinations
Medicaid coverage for sickle cell disease
Issues impacting opioid access/use for patients with hematologic diseases and disorders
Issues related to implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748/P.L. 116-136)
H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
Issues related to telemedicine/telehealth
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Cancer Drug Parity Act (S.741 / H.R.1730)
Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763)
Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507)
Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)
Hematology and oncology drug research and approval issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)
Clinical trials regulations and coverage
Issues impacting coverage for hematologic diseases and conditions
Reimbursement for CAR-T/cellular and gene therapies
Issues impacting opioid access/use for patients with hematologic diseases and disorders
Issues impacting blood safety/shortages
Issues related to convalescent plasma
Healthcare Workforce Resilience Act (H.R. 6788/S. 3599)
Coronavirus Provider Protection Act (H.R. 7059)
H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Leslie |
Brady |
MPH |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Proposals to maintain work authorization for individuals currently in Deferred Action for Childhood Arrivals (DACA) status during the COVID-19 national emergency
Healthcare Workforce Resilience Act (H.R. 6788/S. 3599)
June 22, 2020 Presidential Proclamation Suspending Entry of Aliens Who Present a Risk to the U.S. Labor Market Following the Coronavirus Outbreak
H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Leslie |
Brady |
MPH |
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |